All updated as on -
With a projected CAGR of 9.4% between 2022 and 2030, the global ophthalmic disease therapeutics market is likely to rise from its 2022 valuation of $33.59 billion to a peak of $54.48 billion by 2030. Therapeutics for ophthalmic illnesses include drugs and procedures used to treat conditions like dry eye, glaucoma, and retinal detachment. Demand for innovative medicines and methods of illness management is expected to rise as the population ages and more people are affected by these conditions.
During the anticipated time frame, the effect of COVID-19 on market growth was unfavourable. The temporary closure of orthopaedic clinics and the increased attention of healthcare providers on COVID-19 patients are two main factors responsible for the market's sluggish growth during the pandemic. There was a decrease in patient traffic to hospitals and clinics as a result of the cancellation or postponing of services related to many ocular disorders due to the tight limitations enforced by government authorities across the areas. Because of this, there was a worldwide drop in demand for drugs to treat ocular diseases. The major pharmaceutical companies are investing heavily in the R&D of novel therapies for the treatment of retinal disorders, and more cutting-edge therapies are expected to be approved in the coming years, fueling the growth of the ophthalmic disease therapeutics market. Over-the-counter (OTC) ophthalmic therapeutics are expected to grow in popularity in Asia as a result of the introduction of low-cost ocular drugs by local manufacturers, which will in turn boost sales in the global ophthalmic disease therapeutics market.
The rising incidence of ocular ailments such glaucoma, retinal diseases, dry eye disease, and others is a major contributor to the expanding patient population around the world. Evidence suggests that the elderly are disproportionately affected by eye illnesses. The increased rate of diagnosis and treatment in the population is a result of the combined efforts of numerous healthcare organisations, government bodies, and market partners. Improved efficacy and safety are just two of the many clinical benefits offered by biologics and biosimilars. The higher cost of biologics, increased out-of-pocket expenses, and so on are only a few examples of the constraints that exist. Biologics' greater price tag, resulting from their many advantages and the various costs associated with their development and approval, is a major barrier to their usage in low- and middle-income countries.
Research institutions and industry leaders are ramping up efforts to create and distribute cutting-edge medicines to combat the disease. Demand for therapeutics targeting ophthalmic diseases is expected to rise over the projected period as a consequence of rising investment in research and development by market participants to create novel medicines for the treatment of the condition. Ophthalmic drug consumption is expected to rise as a result of the market's major competitors' increasing focus and active efforts to discover and introduce novel medicines to address the unmet need of the expanding patient population. Strict regulatory frameworks and unclear reimbursement practises impede market growth. Growth in the market is being stymied by a number of factors, including a lack of knowledge about ocular disorders in rural areas and a shortage of health plans that cover corrective lenses. Many people in many parts of the world cannot afford ophthalmology procedures because of how expensive vision care has become. This is seen as the primary reason for the slowing expansion of the global ophthalmology drugs market.
Healthcare organisations and pharmaceutical companies are increasingly devoting resources to R&D in order to create cutting-edge drug delivery systems. One of the primary factors contributing to the shifting emphasis of the market players is the difficulties of current ocular drug delivery systems due to the architecture and physiology of the eye. There has been an uptick in clinical research because universities and hospitals are devoting more resources to discovering and implementing cutting-edge methods of drug administration. Penn Medicine's Department of Ophthalmology reported in 2021 that ophthalmic drug intake might be enhanced by using a synthetic, synthesised protein coating.
Report Coverage
Global Ophthalmic Disease Therapeutics research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Ophthalmic Disease Therapeutics report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Ophthalmic Disease Therapeutics competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Ophthalmic Disease Therapeutics market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Ophthalmic Disease Therapeutics market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Ophthalmic Disease Therapeutics market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Regeneron Pharmaceuticals Inc. (U.S), AbbVie Inc. (U.S.), Santen Pharmaceutical Co. Ltd. (Japan), Novartis AG (Switzerland), Bayer AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Viatris Inc. (U.S.)
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Ophthalmic Disease Therapeutics market based on the below-mentioned segments:
Global Ophthalmic Disease Therapeutics Market, By Drug Class
Anti-inflammatory
Anti-infectives
Anti-VEGF
Anti-glaucoma
Others
Global Ophthalmic Disease Therapeutics market, By Dosage Form
Solid
Liquid
Semisolid
Global Ophthalmic Disease Therapeutics Market, By Distribution Channel
Hospital Pharmacies
Retail & Online Pharmacies
Global Ophthalmic Disease Therapeutics market, Regional Analysis
During the anticipated time frame, the effect of COVID-19 on market growth was unfavourable. The temporary closure of orthopaedic clinics and the increased attention of healthcare providers on COVID-19 patients are two main factors responsible for the market's sluggish growth during the pandemic. There was a decrease in patient traffic to hospitals and clinics as a result of the cancellation or postponing of services related to many ocular disorders due to the tight limitations enforced by government authorities across the areas. Because of this, there was a worldwide drop in demand for drugs to treat ocular diseases. The major pharmaceutical companies are investing heavily in the R&D of novel therapies for the treatment of retinal disorders, and more cutting-edge therapies are expected to be approved in the coming years, fueling the growth of the ophthalmic disease therapeutics market. Over-the-counter (OTC) ophthalmic therapeutics are expected to grow in popularity in Asia as a result of the introduction of low-cost ocular drugs by local manufacturers, which will in turn boost sales in the global ophthalmic disease therapeutics market.
The rising incidence of ocular ailments such glaucoma, retinal diseases, dry eye disease, and others is a major contributor to the expanding patient population around the world. Evidence suggests that the elderly are disproportionately affected by eye illnesses. The increased rate of diagnosis and treatment in the population is a result of the combined efforts of numerous healthcare organisations, government bodies, and market partners. Improved efficacy and safety are just two of the many clinical benefits offered by biologics and biosimilars. The higher cost of biologics, increased out-of-pocket expenses, and so on are only a few examples of the constraints that exist. Biologics' greater price tag, resulting from their many advantages and the various costs associated with their development and approval, is a major barrier to their usage in low- and middle-income countries.
Research institutions and industry leaders are ramping up efforts to create and distribute cutting-edge medicines to combat the disease. Demand for therapeutics targeting ophthalmic diseases is expected to rise over the projected period as a consequence of rising investment in research and development by market participants to create novel medicines for the treatment of the condition. Ophthalmic drug consumption is expected to rise as a result of the market's major competitors' increasing focus and active efforts to discover and introduce novel medicines to address the unmet need of the expanding patient population. Strict regulatory frameworks and unclear reimbursement practises impede market growth. Growth in the market is being stymied by a number of factors, including a lack of knowledge about ocular disorders in rural areas and a shortage of health plans that cover corrective lenses. Many people in many parts of the world cannot afford ophthalmology procedures because of how expensive vision care has become. This is seen as the primary reason for the slowing expansion of the global ophthalmology drugs market.
Healthcare organisations and pharmaceutical companies are increasingly devoting resources to R&D in order to create cutting-edge drug delivery systems. One of the primary factors contributing to the shifting emphasis of the market players is the difficulties of current ocular drug delivery systems due to the architecture and physiology of the eye. There has been an uptick in clinical research because universities and hospitals are devoting more resources to discovering and implementing cutting-edge methods of drug administration. Penn Medicine's Department of Ophthalmology reported in 2021 that ophthalmic drug intake might be enhanced by using a synthetic, synthesised protein coating.
Report Coverage
Global Ophthalmic Disease Therapeutics research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Ophthalmic Disease Therapeutics report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Ophthalmic Disease Therapeutics competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Ophthalmic Disease Therapeutics market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2022 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Regeneron Pharmaceuticals Inc. (U.S), AbbVie Inc. (U.S.), Santen Pharmaceutical Co. Ltd. (Japan), Novartis AG (Switzerland), Bayer AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Viatris Inc. (U.S.) |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Ophthalmic Disease Therapeutics Market from 2021 to 2030.
- Market Forecast for Ophthalmic Disease Therapeutics Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Ophthalmic Disease Therapeutics competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Ophthalmic Disease Therapeutics
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Ophthalmic Disease Therapeutics market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Ophthalmic Disease Therapeutics market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Regeneron Pharmaceuticals Inc. (U.S), AbbVie Inc. (U.S.), Santen Pharmaceutical Co. Ltd. (Japan), Novartis AG (Switzerland), Bayer AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Viatris Inc. (U.S.)
Primary Target Market
- Market Players of Ophthalmic Disease Therapeutics
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Ophthalmic Disease Therapeutics market based on the below-mentioned segments:
Global Ophthalmic Disease Therapeutics Market, By Drug Class
Anti-inflammatory
Anti-infectives
Anti-VEGF
Anti-glaucoma
Others
Global Ophthalmic Disease Therapeutics market, By Dosage Form
Solid
Liquid
Semisolid
Global Ophthalmic Disease Therapeutics Market, By Distribution Channel
Hospital Pharmacies
Retail & Online Pharmacies
Global Ophthalmic Disease Therapeutics market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive ophthalmic disease therapeutics market market research and competitor analysis for your business to help you develop more profound insights into the ophthalmic disease therapeutics market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the ophthalmic disease therapeutics market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.